Miguel González

Miguel González

Auto-generated profile, based on publicly available information

Miguel González

Nephrology Department, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
RERafael de la Espriella
Rafael de la Espriella
ABAntoni Bayés-Genís
Antoni Bayés-Genís
PLPau Llàcer
Pau Llàcer
PPPatricia Palau
Patricia Palau
GMGema Miñana
Gema Miñana
JNJulio Núñez
Julio Núñez

16 August 2023 in Cardiorenal Medicine
Verified
Journal Article
Open access
PDF file
GMGema Miñana
Gema Miñana
MGMiguel González-Rico
Miguel González-Rico
RERafael de la Espriella
Rafael de la Espriella
DGDaniel González-Sánchez
Daniel González-Sánchez
MMMarco Montomoli
Marco Montomoli
JNJulio Núñez
Julio Núñez
Introduction: Spot urinary sodium emerged as a useful parameter for assessing decongestion in patients with congestive heart failure (CHF). Growing evidence endorses the therapeutic role of continuous ambulatory peritoneal dialysis (CAPD) in patients with refractory CHF and kidney disease. We aimed to examine the long-term trajectory of urinary, peritoneal, and total (urinary plus peritoneal) sodium removal in a cohort of patients with refractory CHF enrolled in a CAPD program. Additionally, we explored whether sodium removal was associated with the risk of long-term mortality and episodes of worsening heart failure (WHF). Methods: We included 66 ambulatory patients with refractory CHF enrolled in a CAPD program in a single teaching center. 24-h peritoneal, urinary, and total sodium elimination were analyzed at baseline and after CAPD initiation. Its trajectories over time were calculated using joint modeling of longitudinal and survival data. Within the framework of joint frailty models for recurrent and terminal events, we estimated its prognostic effect on recurrent episodes of WHF. Results: At the time of enrollment, the mean age and estimated glomerular filtration rate were 72.8 ± 8.4 years and 28.5 ± 14.3 mL/min/1.73 m2, respectively. The median urinary sodium at baseline was 2.34 g/day (1.40–3.55). At a median (p25%–p75%) follow-up of 2.93 (1.93–3.72) years, we registered 0.28 deaths and 0.24 episodes of WHF per 1 person-year. Compared to baseline (urinary), CAPD led to increased sodium excretion (urinary plus dialyzed) since the first follow-up visit (p < 0.001). Over the follow-up, repeated measurements of total sodium removal were associated with a lower risk of death and episodes of WHF. Conclusions: CAPD increased sodium removal in patients with refractory CHF. Elevated sodium removal identified those patients with a lower risk of death and episodes of WHF.

25 October 2022 in Cardiorenal Medicine
Verified
Journal Article
Open access
PDF file
RERafael de la Espriella
Rafael de la Espriella
JNJorge Navarro
Jorge Navarro
AMAnna Mollar
Anna Mollar
LDLuis D’mArco
Luis D’mArco
PPPatricia Palau
Patricia Palau
JNJulio Núñez
Julio Núñez
Introduction: Although small-sample size studies have shown that basal alterations of estimated glomerular filtration rate (eGFR) are related to short- and mid-term higher mortality in acute heart failure (AHF), there is scarce information on the influence of an altered eGFR on long-term mortality and readmissions. Therefore, this multicenter study sought to investigate the relationship between eGFR on admission for AHF and both long-term mortality and readmissions in a large sample of patients. Methods: We retrospectively evaluated 4,595 patients consecutively discharged after admission for AHF at three tertiary-care hospitals from January 1, 2008, to January 1, 2020. To investigate the effect of eGFR on admission with long-term morbimortality, we stratified the patients according to four eGFR categories: <30 mL·min−1·1.73 m−2 (G4 and G5 patients, n = 534), 30–44 mL·min−1·1.73 m−2 (G3b patients, n = 882), 45–59 mL·min−1·1.73 m−2 (G3a patients, n = 1,080), and ≥60 mL·min−1·1.73 m−2 (G1 and G2 patients, n = 2,099). eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation within the first 24 h following admission. Results: At a median follow-up of 2.20 years, multivariate analyses revealed that compared to G1 and G2 patients, G4 and G5 patients exhibited a higher risk of all-cause (HR = 1.15, 95% CI: 01.02–1.30, p = 0.020) and cardiovascular (CV) (HR = 1.20, 95% CI: 1.04–1.39, p = 0.013) mortality. Similarly, multivariate analyses also showed that the lower the eGFR, the higher the risk of readmissions. In fact, compared to G1 and G2 patients, G4 and G5 patients displayed significantly increased incident rate ratios of total all-cause (28%), CV (26%), and HF-related (30%) readmissions. Conclusion: Data from this large study provide evidence that an eGFR below 30 mL·min−1·1.73 m−2 on admission could be an independent predictor for long-term mortality and readmissions in patients with AHF.

1 January 2025 in Cardiorenal Medicine
Verified
Journal Article
Open access
MMMarco Montomoli
Marco Montomoli
MRMiguel Gonzalez Ricoa
Miguel Gonzalez Ricoa
JGJose Luis Gorriz
Jose Luis Gorriz
MMMaria Jesus Puchades Montesa
Maria Jesus Puchades Montesa
GMGonzalo Nuñez Marín
Gonzalo Nuñez Marín
MLMaria Soledad Lecueder
Maria Soledad Lecueder
Background: Renal sodium avidity is a defining characteristic of chronic cardiorenal syndrome (CRS), leading to persistent sodium retention despite significant fluid overload. This phenomenon exacerbates volume overload, contributes to hemodynamic instability, and accelerates the decline of cardiac and renal function. Conventional diuretic therapies, though effective in acute settings, often fail chronically due to neurohormonal activation, renal tubular adaptations, and diuretic resistance. Summary: This review explores innovative approaches to overcoming natriuresis and diuresis resistance in CRS patients. Emerging pharmacological treatments, including sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor (GLP-1R) agonists, show potential in enhancing sodium excretion. Additionally, extracorporeal techniques such as ultrafiltration (UF) via hemodialysis and peritoneal dialysis (PD) provide precise sodium and fluid removal, bypassing many of the limitations of traditional pharmacotherapy. PD, in particular, has demonstrated efficacy in refractory cases by preserving residual renal function and improving diuretic responsiveness. As the saying goes, “there’s always more than one way to skin a cat.” Key Messages: (1) Renal sodium avidity plays a crucial role in CRS progression, necessitating targeted interventions. (2) Standard diuretic therapies often fail to provide sustained relief due to compensatory mechanisms. (3) Novel pharmacological agents (SGLT2 inhibitors, GLP-1R agonists) and extracorporeal techniques (UF, PD) offer promising alternatives for managing sodium retention and fluid overload. (4) A multidisciplinary and personalized treatment strategy is essential for optimizing patient outcomes and improving quality of life.

1 July 2006
Verified
Conference Paper
Closed access
Antonio Moreno-MunozAntonio Moreno-Munoz
Antonio Moreno-Munoz
DODaniel Oterino
Daniel Oterino
MGMiguel Gonzalez
Miguel Gonzalez
FPFERNANDO AGUSTIN OLIVENCIA POLO
FERNANDO AGUSTIN OLIVENCIA POLO
Juan-José González-de-la-RosaJuan-José González-de-la-Rosa
Juan-José González-de-la-Rosa
Voltage dip analysis is a complex stochastic issue, since it involves a large variety of random factors: type of short-circuits in the power system, location of faults, protective system performance and atmospheric discharges. Among all categories of electrical disturbances, the voltage dip (sag) and momentary interruption are the nemeses of the automated industrial process. The dynamic voltage restorer (DVR) is a static series compensator (SSC) suitable for protecting industrial plant against voltage dip. This paper presents results about comparative analysis of three compensation techniques like in-phase compensation method, pre-dip compensation method (called too voltage difference compensation), and phase advance compensation method. To validate the effectiveness of each method, several disturbance scenarios including supply voltage drop and power factor of the load were examined. In particular, the paper analyzes the effect on necessary active power and voltage injected.